This is a Phase 1, first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of ORKA-002 in healthy participants.
This is a single center, Phase 1, double-blind, placebo-controlled, randomized, first-in-human (FIH), single ascending dose study evaluating the safety, tolerability, pharmacokinetics (PK) of ORKA-002 in healthy volunteers. The study will enroll approximately 24 healthy volunteers. The ORKA-002 dose will be administered by a subcutaneous injection.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Enrollment
24
Oruka Therapeutics Investigative Site
Christchurch, New Zealand, New Zealand
Incidence of Treatment-emergent Adverse Events
Incidence of treatment-emergent adverse events and clinically significant changes from baseline in vital signs, electrocardiograms, and clinical laboratory parameters
Time frame: Day 1 through 1 year
Maximum observed serum concentration of ORKA-002
Cmax of ORKA-002
Time frame: Day 1 through 1 year
Time to Cmax (Tmax) of ORKA-002
Tmax of ORKA-002
Time frame: Day 1 through 1 year
Area under the serum concentration-time curve (AUC) of ORKA-002
Area under the curve from the time of dosing to infinity (AUC0-inf)
Time frame: Day 1 through 1 year
Terminal elimination half-life (T1/2)
T1/2 of ORKA-002
Time frame: Day 1 through 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.